| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg | |||
| 10mg | |||
| Other Sizes |
| Targets |
SARS-CoV-IN-2 targets SARS-CoV, the virus responsible for severe acute respiratory syndrome, through inhibition of viral replication. As a hydroxyferroquine derivative, it also targets Plasmodium falciparum by interfering with heme detoxification. The compound may also have activity against HIV-1, as it reduces HIV-1-induced cytopathic effects. The mechanism involves inhibition of SARS-CoV protease and disruption of parasitic heme metabolism.
|
|---|---|
| ln Vitro |
SARS-CoV-IN-2 (compound 3) is significantly more effective than chloroquine (CQ) at preventing Plasmodium falciparum from growing in vitro [1].
In vitro, SARS-CoV-IN-2 is antiviral against SARS-CoV with an EC50 of 1.9 microM in Vero cells. It inhibits P. falciparum 3D7 and W2 strains with IC50s of 21.5 and 30 nM, respectively, and IC90s of 51.0 and 99.9 nM, respectively. In MT-4 cells, SARS-CoV-IN-2 reduces HIV-1-induced cytopathic effects with an EC50 of 2.9 microM. It is significantly more effective than chloroquine at preventing P. falciparum growth in vitro and possesses antimalarial and anti-viral effects. |
| ln Vivo |
No specific in vivo activity data is available for SARS-CoV-IN-2. The compound is primarily studied in cell-based in vitro systems for antiviral, anti-HIV, and antiplasmodial activity.
|
| Enzyme Assay |
For in vitro antiviral assays: Infect Vero cells with SARS-CoV at an appropriate MOI. Treat cells with SARS-CoV-IN-2 at concentrations ranging from 0.1-100 microM. Incubate for 48-72 hours. Measure viral replication by plaque assay or qRT-PCR for viral RNA. Calculate EC50 values. For anti-HIV assays: Infect MT-4 cells with HIV-1. Treat with SARS-CoV-IN-2 at varying concentrations. Assess inhibition of HIV-1-induced cytopathic effects by MTT or XTT assay after 5-7 days. Calculate EC50. For antiplasmodial assays: Culture P. falciparum 3D7 and W2 strains in human red blood cells. Treat with SARS-CoV-IN-2 (1-1000 nM) for 48-72 hours. Measure parasite growth inhibition by HRP2 ELISA or 3H-hypoxanthine incorporation. Calculate IC50 and IC90 values.
|
| Animal Protocol |
No specific in vivo protocol exists. The compound may be studied in mouse malaria models (e.g., P. berghei) with intraperitoneal administration, or in SARS-CoV animal models with intranasal or intraperitoneal administration. These protocols require validation.
|
| ADME/Pharmacokinetics |
The compound is soluble in DMSO at 19.23 mg/mL (42.20 mM). For in vivo formulation, it can be prepared in 10% DMSO + 90% (20% SBE-beta-CD in saline) at ≥1.92 mg/mL. As a powder, store at -20degC for up to 3 years, or in solvent at -80degC for 6 months.
|
| Toxicity/Toxicokinetics |
No specific toxicity data is available. Standard laboratory safety precautions should be followed. Resistance mechanisms are expected to be similar to other protease inhibitors, with potential mutations in viral protease genes. The compound is for research use only.
|
| References | |
| Additional Infomation |
SARS-CoV-IN-2 is a research-grade compound for laboratory use only, not for human therapeutic applications. It is used as a tool to study SARS-CoV replication and as a potential lead compound for antiviral drug development. It also serves as a reference for studying hydroxyferroquine derivatives with dual antimalarial and antiviral activities. The compound should be stored at -20degC, protected from light and moisture. It is soluble in DMSO. No clinical trials or approved status exist.
|
| Molecular Formula |
C24H18CLFEN3O
|
|---|---|
| Molecular Weight |
455.72
|
| CAS # |
888958-26-7
|
| Appearance |
Light yellow to yellow solid powder
|
| SMILES |
C(N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)O)CC(C)C)(=O)[C@]([H])([C@H](O)C)NC(=O)[C@H](C)NC([C@@H]1CCCN1C(=O)CNC(=O)CNC(=O)CN)=O
|
| Synonyms |
SARSCoVIN2; SARS CoV IN 2
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~19.23 mg/mL (~42.20 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.92 mg/mL (4.21 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 19.2 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1943 mL | 10.9716 mL | 21.9433 mL | |
| 5 mM | 0.4389 mL | 2.1943 mL | 4.3887 mL | |
| 10 mM | 0.2194 mL | 1.0972 mL | 2.1943 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
